Headache News and Research

Latest Headache News and Research

AbbVie submits NDA in Japan for investigational, all-oral treatment of patients with chronic HCV infection

AbbVie (NYSE: ABBV) submitted a New Drug Application (NDA) to the Japanese Ministry of Health, Labour and Welfare (MHLW) seeking approval for the company's investigational, all-oral, ribavirin (RBV) and interferon (IFN)-free, 12-week, two direct-acting antiviral treatment of ombitasvir/paritaprevir/ritonavir (OBV/PTV/r), dosed once daily.

12 Feb 2015

Diamond Headache Clinic's Alexander Feoktistov named recipient of 2015 NHF Lectureship

The National Headache Foundation is pleased to announce that Alexander Feoktistov, M.D., Ph.D., Director of Research at Diamond Headache Clinic, Chicago, Illinois, has been named the recipient of the 2015 NHF Lectureship. As the premier educational and informational resource for those living with headache disorders, their family members, physicians, allied health professionals, and health policy decision makers, the NHF created this award to preserve the highest level of neurobiological research and advancement in medicine today.

11 Feb 2015

Sign/symptom-based measures could help patients receive timely care

An examination of process measures endorsed by the National Quality Forum finds that these measures focus predominantly on management of patients with established diagnoses, and that quality measures for patient presenting symptoms often do not reflect the most common reasons patients seek care, according to a study in the February 3 issue of JAMA.

9 Feb 2015

Epidemiologist urges people to get vaccinated against measles

Americans may be victims of their own success when it comes to the eradication of infectious diseases and take their disease-free lives for granted, says Jorge Parada, MD, hospital epidemiologist and medical director of the Infection Prevention and Control program at Loyola University Health System.

4 Feb 2015

AbbVie releases Phase 3 results from all-oral OBV/PTV/r treatment for GT1b chronic HCV infection

AbbVie released top-line Phase 3 results for its investigational, all-oral, ribavirin (RBV)-free, two direct-acting antiviral treatment with ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) in patients with genotype 1b (GT1b) chronic hepatitis C virus (HCV) infection in Japan.

31 Jan 2015

electroCore’s non-invasive vagus nerve stimulation therapy safe, effective across a variety of conditions

Non-invasive vagus nerve stimulation (nVNS) ‘improves the safety and tolerability of VNS making it more accessible and facilitating further investigations across a wide range of uses when compared with surgically implanted VNS’ according to a review in the European Journal of Neurology.

29 Jan 2015

AHS provides updated assessment of treatments for acute migraine

The January issue of the American Headache Society journal Headache provides an updated assessment of the best treatments to use when a migraine attack occurs. The assessment will form the basis of new AHS treatment guidelines.

21 Jan 2015

Two new ODYSSEY trials meet primary efficacy endpoints

Regeneron Pharmaceuticals, Inc. and Sanofi today announced that two new ODYSSEY trials, which are the first Phase 3 trials to assess alirocumab administered every four weeks, met their primary efficacy endpoints.

9 Jan 2015

FDA approves RYTARY for Parkinson's disease treatment

Impax Pharmaceuticals, a division of Impax Laboratories, Inc., today announced that the U.S. Food and Drug Administration approved RYTARY, an extended-release oral capsule formulation of carbidopa-levodopa, for the treatment of Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication and / or manganese intoxication.

8 Jan 2015

American Migraine Foundation plans to create Migraine Patient Registry and Biorepository

Migraine affects 36 million Americans, can have a major impact on patients' quality of life, and even on their relationships. The World Health Organization estimates that migraine is the third most prevalent medical disorder in the world, the 4th most disabling among women and the 7th most disabling overall.

8 Jan 2015

Improving headache treatment could reduce health care spending, new study suggests

Each year more than 12 million Americans visit their doctors complaining of headaches, which result in lost productivity and costs of upward of $31 billion annually. A new study by researchers from Beth Israel Deaconess Medical Center suggests some of that cost could be offset by physicians ordering fewer tests and an increased focus on counseling about lifestyle changes.

8 Jan 2015

Additional products seized from Calgary stores contain undeclared drug ingredients

Further to its recent Advisory, Health Canada has identified additional products seized from two Samson's Supplements stores in Calgary that pose a risk to health.

2 Jan 2015

Sex enhancement product recalled after Health Canada test finds undeclared drug ingredient

One lot of the sex enhancement product "Forta for Men" (NPN 80045132) is being recalled after Health Canada testing confirmed it contains an undeclared drug: homosildenafil.

31 Dec 2014

FDA approves Hospira's Dyloject (diclofenac sodium) Injection for pain management

Hospira, Inc., the world's leading provider of injectable drugs and infusion technologies, and a global leader in biosimilars, has received approval from the U.S. Food and Drug Administration for Dyloject (diclofenac sodium) Injection, a proprietary nonsteroidal anti-inflammatory drug (NSAID) analgesic.

30 Dec 2014

Janssen, Gilead to jointly develop darunavir-based, single-tablet regimen for HIV treatment

Janssen R&D Ireland announced today an amendment to its existing agreement with Gilead Sciences, Inc., initially established in 2011, for the development of a once daily, darunavir-based, single-tablet regimen (STR) for the treatment of people living with HIV.

29 Dec 2014

Protein Sciences earns Frost & Sullivan 2013 Global New Product Innovation Award

Based on its recent analysis of the influenza vaccines market, Frost & Sullivan recognises Protein Sciences with the 2013 Global New Product Innovation Award. Flublok is the world's first recombinant protein vaccine for the prevention of seasonal influenza disease to gain U.S. FDA approval.

29 Dec 2014

United Therapeutics submits pre-market approval application for use of Remodulin with implantable drug infusion system

United Therapeutics Corporation (NASDAQ: UTHR) announced today that Medtronic, Inc. (NYSE: MDT) has submitted a pre-market approval application to the U.S. Food and Drug Administration (FDA) for the use of Medtronic's SynchroMed® II implantable drug infusion system (including a newly developed catheter) for use with United Therapeutics' Remodulin® (treprostinil) Injection delivered intravenously to patients with pulmonary arterial hypertension.

25 Dec 2014

FDA approves Novo Nordisk’s weight loss injection, Saxenda

Novo Nordisk today announced that the Food and Drug Administration (FDA) has approved the new drug application (NDA) for Saxenda® (liraglutide [rDNA origin] injection), the first once-daily glucagon-like peptide-1 (GLP-1) receptor agonist for chronic weight management.

25 Dec 2014

FDA approves Namzaric drug for treatment of moderate to severe Alzheimer's disease

Actavis plc and Adamas Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Namzaric, a fixed-dose combination (FDC) of memantine hydrochloride extended-release, a NMDA receptor antagonist, and donepezil hydrochloride, an acetylcholinesterase inhibitor.

25 Dec 2014

Hospital treatment far from home: an interview with Paul Lindsell, Managing Director at MindMetre Research

This is a generally accepted piece of received wisdom amongst clinicians and care professionals, which MindMetre validated through a series of qualitative interviews that preceded our quantitative study.

21 Dec 2014

Headache News and Research

Latest Headache News and Research

AbbVie submits NDA in Japan for investigational, all-oral treatment of patients with chronic HCV infection

Diamond Headache Clinic's Alexander Feoktistov named recipient of 2015 NHF Lectureship

Sign/symptom-based measures could help patients receive timely care

Epidemiologist urges people to get vaccinated against measles

AbbVie releases Phase 3 results from all-oral OBV/PTV/r treatment for GT1b chronic HCV infection

electroCore’s non-invasive vagus nerve stimulation therapy safe, effective across a variety of conditions

AHS provides updated assessment of treatments for acute migraine

Two new ODYSSEY trials meet primary efficacy endpoints

FDA approves RYTARY for Parkinson's disease treatment

American Migraine Foundation plans to create Migraine Patient Registry and Biorepository

Improving headache treatment could reduce health care spending, new study suggests

Additional products seized from Calgary stores contain undeclared drug ingredients

Sex enhancement product recalled after Health Canada test finds undeclared drug ingredient

FDA approves Hospira's Dyloject (diclofenac sodium) Injection for pain management

Janssen, Gilead to jointly develop darunavir-based, single-tablet regimen for HIV treatment

Protein Sciences earns Frost & Sullivan 2013 Global New Product Innovation Award

United Therapeutics submits pre-market approval application for use of Remodulin with implantable drug infusion system

FDA approves Novo Nordisk’s weight loss injection, Saxenda

FDA approves Namzaric drug for treatment of moderate to severe Alzheimer's disease

Hospital treatment far from home: an interview with Paul Lindsell, Managing Director at MindMetre Research

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Headache News and Research

Latest Headache News and Research

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in